HRP20180936T1 - Analozi glukagona koji pokazuju aktivnost prema receptoru za gip - Google Patents

Analozi glukagona koji pokazuju aktivnost prema receptoru za gip

Info

Publication number
HRP20180936T1
HRP20180936T1 HRP20180936TT HRP20180936T HRP20180936T1 HR P20180936 T1 HRP20180936 T1 HR P20180936T1 HR P20180936T T HRP20180936T T HR P20180936TT HR P20180936 T HRP20180936 T HR P20180936T HR P20180936 T1 HRP20180936 T1 HR P20180936T1
Authority
HR
Croatia
Prior art keywords
analogs
receptor activity
gip receptor
glucagon
exhibiting gip
Prior art date
Application number
HRP20180936TT
Other languages
English (en)
Croatian (hr)
Inventor
Richard D. Dimarchi
David L. Smiley
Konrad H. BLEICHER
Eric A. Kitas
Original Assignee
Indiana University Research And Technology Corporation
Novo Nordisk A/S
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Indiana University Research And Technology Corporation, Novo Nordisk A/S filed Critical Indiana University Research And Technology Corporation
Publication of HRP20180936T1 publication Critical patent/HRP20180936T1/hr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measurement And Recording Of Electrical Phenomena And Electrical Characteristics Of The Living Body (AREA)
  • Measuring Pulse, Heart Rate, Blood Pressure Or Blood Flow (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
HRP20180936TT 2012-06-21 2013-06-18 Analozi glukagona koji pokazuju aktivnost prema receptoru za gip HRP20180936T1 (hr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201261662874P 2012-06-21 2012-06-21
US201361787973P 2013-03-15 2013-03-15
EP13731246.8A EP2864350B1 (en) 2012-06-21 2013-06-18 Analogs of glucagon exhibiting gip receptor activity
PCT/US2013/046229 WO2013192130A1 (en) 2012-06-21 2013-06-18 Analogs of glucagon exhibiting gip receptor activity

Publications (1)

Publication Number Publication Date
HRP20180936T1 true HRP20180936T1 (hr) 2018-12-14

Family

ID=48692696

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20180936TT HRP20180936T1 (hr) 2012-06-21 2013-06-18 Analozi glukagona koji pokazuju aktivnost prema receptoru za gip

Country Status (30)

Country Link
US (2) US9868772B2 (OSRAM)
EP (1) EP2864350B1 (OSRAM)
JP (1) JP6300239B2 (OSRAM)
KR (1) KR20150039748A (OSRAM)
CN (1) CN104583233B (OSRAM)
AR (1) AR091478A1 (OSRAM)
AU (1) AU2013277372B2 (OSRAM)
BR (1) BR112014031671A2 (OSRAM)
CA (1) CA2877127A1 (OSRAM)
CL (1) CL2014003421A1 (OSRAM)
CO (1) CO7170125A2 (OSRAM)
CR (1) CR20150015A (OSRAM)
DK (1) DK2864350T3 (OSRAM)
EA (1) EA029025B1 (OSRAM)
ES (1) ES2674946T3 (OSRAM)
HR (1) HRP20180936T1 (OSRAM)
HU (1) HUE039267T2 (OSRAM)
IL (1) IL236386B (OSRAM)
MX (1) MX356000B (OSRAM)
MY (1) MY185217A (OSRAM)
PE (1) PE20150863A1 (OSRAM)
PH (1) PH12014502857A1 (OSRAM)
PL (1) PL2864350T3 (OSRAM)
PT (1) PT2864350T (OSRAM)
RS (1) RS57347B1 (OSRAM)
SG (1) SG11201408491SA (OSRAM)
SI (1) SI2864350T1 (OSRAM)
TR (1) TR201808818T4 (OSRAM)
TW (1) TWI644920B (OSRAM)
WO (1) WO2013192130A1 (OSRAM)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE060743T2 (hu) 2012-04-26 2023-04-28 Bristol Myers Squibb Co Gyógyszerészeti kompozíciók, amelyek tartalmaznak imidazothiadiazol- és imidazopiridazinszármazékokat mint proteáz aktívált receptor 4 (PAR4) inhibitorokat trombocitaaggregációk kezelésére
RS57347B1 (sr) * 2012-06-21 2018-08-31 Univ Indiana Res & Tech Corp Analozi glukagona koji ispoljavaju aktivnost gip receptora
UA116217C2 (uk) 2012-10-09 2018-02-26 Санофі Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону
HRP20181300T1 (hr) 2012-12-21 2018-10-05 Sanofi Derivati eksendina-4 kao dvostruki glp1/gip- ili trostruki glp1/gip/glukagon agonisti
UA118558C2 (uk) 2013-05-28 2019-02-11 Такеда Фармасьютікал Компані Лімітед Пептидна сполука
EP3080149A1 (en) 2013-12-13 2016-10-19 Sanofi Dual glp-1/glucagon receptor agonists
TW201609796A (zh) 2013-12-13 2016-03-16 賽諾菲公司 非醯化之艾塞那肽－４（ｅｘｅｎｄｉｎ－４）胜肽類似物
WO2015086728A1 (en) 2013-12-13 2015-06-18 Sanofi Exendin-4 peptide analogues as dual glp-1/gip receptor agonists
EP3080154B1 (en) 2013-12-13 2018-02-07 Sanofi Dual glp-1/gip receptor agonists
US10137170B2 (en) 2013-12-20 2018-11-27 Indiana University Research And Technology Corporation Lipidated incretin receptor ligand human immunoglobulin Fc-region fusion polypeptides
TW201625669A (zh) 2014-04-07 2016-07-16 賽諾菲公司 衍生自艾塞那肽－４（Ｅｘｅｎｄｉｎ－４）之肽類雙重ＧＬＰ－１／升糖素受體促效劑
TW201625670A (zh) 2014-04-07 2016-07-16 賽諾菲公司 衍生自ｅｘｅｎｄｉｎ－４之雙重ｇｌｐ－１／升糖素受體促效劑
TW201625668A (zh) 2014-04-07 2016-07-16 賽諾菲公司 作為胜肽性雙重ｇｌｐ－１／昇糖素受體激動劑之艾塞那肽－４衍生物
US9932381B2 (en) 2014-06-18 2018-04-03 Sanofi Exendin-4 derivatives as selective glucagon receptor agonists
EA201790914A1 (ru) 2014-10-24 2017-08-31 Мерк Шарп И Доум Корп. Коагонисты рецепторов глюкагона и glp-1
US11135271B2 (en) 2014-12-30 2021-10-05 Hanmi Pharm. Co., Ltd. Glucagon derivatives with improved stability
AR105319A1 (es) 2015-06-05 2017-09-27 Sanofi Sa Profármacos que comprenden un conjugado agonista dual de glp-1 / glucagón conector ácido hialurónico
AU2016287209B2 (en) 2015-06-30 2023-03-02 Hanmi Pharm. Co., Ltd. Glucagon derivative and a composition comprising a long acting conjugate of the same
AR105284A1 (es) 2015-07-10 2017-09-20 Sanofi Sa Derivados de exendina-4 como agonistas peptídicos duales específicos de los receptores de glp-1 / glucagón
TWI622596B (zh) 2015-10-26 2018-05-01 美國禮來大藥廠 升糖素受體促效劑
ES2968038T3 (es) 2015-12-23 2024-05-06 Univ Johns Hopkins Agonista GLP-1R de acción prolongada como terapia de afecciones neurológicas y neurodegenerativas
PT3398961T (pt) * 2015-12-31 2022-09-05 Hanmi Pharm Ind Co Ltd Ativador triplo ativando recetor glucagon, glp-1 e gip
JP6995042B2 (ja) 2016-05-24 2022-02-04 武田薬品工業株式会社 ペプチド化合物
JP7208020B2 (ja) 2016-06-29 2023-01-18 ハンミ ファーマシューティカル カンパニー リミテッド グルカゴン誘導体、その結合体、及びそれを含む組成物、並びにその治療的用途
TW201833132A (zh) 2016-12-02 2018-09-16 法商賽諾菲公司 作為肽類ｇｌｐ１／升糖素／ｇｉｐ三重受體激動劑之新穎化合物
TW201833131A (zh) 2016-12-02 2018-09-16 法商賽諾菲公司 作為胜肽類ｇｌｐ１／升糖素／ｇｉｐ受體促效劑之新化合物
JOP20180028A1 (ar) 2017-03-31 2019-01-30 Takeda Pharmaceuticals Co مركب ببتيد
CN115304666B (zh) * 2017-11-24 2025-09-19 浙江道尔生物科技有限公司 一种治疗代谢疾病的胰高血糖素类似物
US11028123B2 (en) 2018-04-10 2021-06-08 Sanofi-Aventis Deutschland Gmbh Capping of unprotected amino groups during peptide synthesis
WO2019197466A1 (en) 2018-04-10 2019-10-17 Sanofi-Aventis Deutschland Gmbh Method for cleavage of solid phase-bound peptides from the solid phase
SG11202010297UA (en) * 2018-05-04 2020-11-27 Novo Nordisk As Gip derivatives and uses thereof
TW202015735A (zh) 2018-05-30 2020-05-01 法商賽諾菲公司 包含ｇｌｐ－１／升糖素／ｇｉｐ三重受體促效劑、連接子及透明質酸之接合物
CA3178366A1 (en) * 2018-07-23 2020-01-30 Eli Lilly And Company Gip/glp1 co-agonist compounds
US11166910B2 (en) 2019-01-25 2021-11-09 Nordiccan A/S Cannabinoid chewing gum with sugar alcohols
AU2020431973A1 (en) * 2020-02-24 2022-09-22 Shenzhen Turier Biotech Co., Ltd. Polypeptide compound and application thereof in prevention or treatment of diabetes or diabetes complication
PH12022552562A1 (en) * 2020-03-25 2022-12-19 Takeda Pharmaceuticals Co Qd dosing of gip receptor agonist peptide compounds and uses thereof
CN113493503B (zh) * 2020-04-08 2022-08-05 浙江道尔生物科技有限公司 一种肠促胰岛素类似物及其制备方法和用途
US20230272029A1 (en) 2020-07-22 2023-08-31 Novo Nordisk A/S Co-agonists at glp-1 and gip receptors suitable for oral delivery
CN114621327B (zh) * 2020-12-10 2023-08-18 江苏中新医药有限公司 GLP-1、GIP和Gcg多重受体激动蛋白质
KR20230126712A (ko) 2020-12-23 2023-08-30 제지앙 도어 바이오로직스 코., 엘티디. 지속형 글루카곤 유도체
WO2022156189A1 (zh) * 2021-01-22 2022-07-28 深圳市图微安创科技开发有限公司 多肽化合物在预防或治疗炎症性肠病及其相关的肠纤维化中的应用
CA3226003A1 (en) * 2021-07-16 2023-01-19 Pep2Tango Therapeutics Inc. Compositions including multi-agonist peptides and methods of manufacture and use
TW202330584A (zh) 2022-01-20 2023-08-01 丹麥商諾佛 儂迪克股份有限公司 前藥及其用途
CN115490760B (zh) * 2022-07-04 2023-04-14 北京惠之衡生物科技有限公司 一种glp-1受体和gcg受体共激动多肽衍生物
JP7402574B1 (ja) 2023-03-15 2023-12-21 株式会社合同資源 α－ヨード置換カルボン酸

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4450150A (en) 1973-05-17 1984-05-22 Arthur D. Little, Inc. Biodegradable, implantable drug delivery depots, and method for preparing and using the same
JPS63502716A (ja) 1986-03-07 1988-10-13 マサチューセッツ・インステチュート・オブ・テクノロジー 糖タンパク安定性の強化方法
IN165717B (OSRAM) 1986-08-07 1989-12-23 Battelle Memorial Institute
JP3266311B2 (ja) 1991-05-02 2002-03-18 生化学工業株式会社 新規ポリペプチドおよびこれを用いる抗ｈｉｖ剤
CA2320193A1 (en) 1998-02-10 1999-08-19 Welfide Corporation Controlled release preparation
GB2344287A (en) 1998-12-03 2000-06-07 Ferring Bv Controlled release pharmaceutical formulation
SE0302312D0 (sv) * 2002-10-04 2003-08-27 Forskarpatent I Syd Ab Peptide-based passive immunization therapy for treatment of atherosclerosis
ATE458534T1 (de) 2002-10-04 2010-03-15 Microchips Inc Medizinische vorrichtung zur gesteuerten arzneimittelverabreichung sowie herzüberwachung und/oder herzstimulation
JP2006524039A (ja) 2003-01-09 2006-10-26 マクロジェニクス，インコーポレーテッド 変異型Ｆｃ領域を含む抗体の同定および作製ならびにその利用法
TWI353991B (en) 2003-05-06 2011-12-11 Syntonix Pharmaceuticals Inc Immunoglobulin chimeric monomer-dimer hybrids
US7846445B2 (en) 2005-09-27 2010-12-07 Amunix Operating, Inc. Methods for production of unstructured recombinant polymers and uses thereof
AU2007249736A1 (en) 2006-05-15 2007-11-22 Wisconsin Alumni Research Foundation Pulmonary delivery of 1alpha,25-dihydroxyvitamin D3 and co-administration of parathyroid hormone or calcitonin
FR2902092B1 (fr) 2006-06-07 2008-09-05 Sapelem Soc Par Actions Simpli Appareil de manutention de charge
BRPI0807728A2 (pt) 2007-02-15 2012-04-17 Univ Indiana Res & Tech Corp co-agonistas de receptor glucagon/glp-1
NZ580700A (en) 2007-04-19 2012-01-12 Dong A Pharm Co Ltd A biodegradable microsphere composition suitable for the controlled release of glucose controlling peptide and formulation thereof
BRPI0815416A2 (pt) 2007-08-15 2014-10-21 Amunix Inc Composições e métodos para modificar propriedades de polipeptídeos biologicamente ativos
SG192405A1 (en) * 2008-06-17 2013-08-30 Univ Indiana Res & Tech Corp Gip-based mixed agonists for treatment of metabolic disorders and obesity
CN102123723B (zh) * 2008-06-17 2016-05-25 印第安纳大学研究及科技有限公司 胰高血糖素/glp-1受体共激动剂
EP2376097A4 (en) 2008-12-19 2012-10-03 Univ Indiana Res & Tech Corp PEPTIDE PRODRUGS OF AMIDE-BASED GLUCAGON SUPERFAMILY
RU2012101274A (ru) 2009-06-16 2013-07-27 Индиана Юниверсити Рисерч Энд Текнолоджи Корпорейшн Соединения глюкагона, активные в отношении рецептора gip
MX2012008603A (es) 2010-01-27 2013-01-25 Univ Indiana Res & Tech Corp Conjugados de antagonista de glucagon-agonista de gip y composiciones para el tratamiento de desordenes metabolicos y obesidad.
WO2011143209A1 (en) * 2010-05-13 2011-11-17 Indiana University Research And Technology Corporation Glucagon superfamily peptides exhibiting nuclear hormone receptor activity
MX2012014576A (es) * 2010-06-24 2013-02-21 Univ Indiana Res & Tech Corp Profarmacos de peptido de la superfamilia de glucagon basado en amida.
US9156902B2 (en) * 2011-06-22 2015-10-13 Indiana University Research And Technology Corporation Glucagon/GLP-1 receptor co-agonists
BR112013032717A2 (pt) * 2011-06-22 2017-01-24 Univ Indiana Res & Tech Corp coagonistas do receptor de glucagon/glp-1
RS57347B1 (sr) * 2012-06-21 2018-08-31 Univ Indiana Res & Tech Corp Analozi glukagona koji ispoljavaju aktivnost gip receptora
WO2016049190A1 (en) * 2014-09-24 2016-03-31 Indiana University Research And Technology Corporation Incretin-insulin conjugates

Also Published As

Publication number Publication date
AU2013277372A1 (en) 2014-12-11
TW201402603A (zh) 2014-01-16
PE20150863A1 (es) 2015-06-11
EP2864350A1 (en) 2015-04-29
CR20150015A (es) 2015-04-24
ES2674946T3 (es) 2018-07-05
US9868772B2 (en) 2018-01-16
IL236386B (en) 2019-09-26
CN104583233A (zh) 2015-04-29
JP2015528795A (ja) 2015-10-01
SG11201408491SA (en) 2015-01-29
CA2877127A1 (en) 2013-12-27
HUE039267T2 (hu) 2018-12-28
TWI644920B (zh) 2018-12-21
WO2013192130A1 (en) 2013-12-27
AR091478A1 (es) 2015-02-04
PL2864350T3 (pl) 2019-01-31
EA201590065A1 (ru) 2015-07-30
US20180105569A1 (en) 2018-04-19
IL236386A0 (en) 2015-02-26
KR20150039748A (ko) 2015-04-13
TR201808818T4 (tr) 2018-07-23
JP6300239B2 (ja) 2018-03-28
MY185217A (en) 2021-04-30
BR112014031671A2 (pt) 2018-08-07
MX2014015556A (es) 2015-03-05
CL2014003421A1 (es) 2015-05-22
CO7170125A2 (es) 2015-01-28
EP2864350B1 (en) 2018-03-28
EA029025B1 (ru) 2018-01-31
CN104583233B (zh) 2018-10-23
SI2864350T1 (en) 2018-08-31
PH12014502857A1 (en) 2015-02-23
DK2864350T3 (en) 2018-05-28
RS57347B1 (sr) 2018-08-31
MX356000B (es) 2018-05-08
US20150368310A1 (en) 2015-12-24
AU2013277372B2 (en) 2018-03-29
PT2864350T (pt) 2018-05-14

Similar Documents

Publication Publication Date Title
IL236386B (en) Gip Glucagon analogs exhibiting receptor activity
ZA201702364B (en) Glucagon analogues
BR112015005783A8 (pt) análogos de glucagon
IL238578B (en) Spliceostatin analogs
BR112014015681A2 (pt) análogos de glucagon
IL231199A0 (en) New analogs of glucagon
PT2866825T (pt) Uso de péptidos glp-1 de longa ação
EP2798808A4 (en) TRANSFER OF A COMMUNICATION EVENT
BR112013024076A2 (pt) análogos de glucagon
EP2798779A4 (en) TRANSFER OF A COMMUNICATION EVENT
EP2864361A4 (en) DOSAGE REGIME OF FUSION COMPOUNDS
LT2833884T (lt) Ccr3-inhibitorių panaudojimas
PT3055315T (pt) Tiazolopirimidonas enquanto moduladores da atividade do recetor nmda
EP2800747A4 (en) POLYMORPHY OF PERAMPANEL
IL238080A0 (en) Somatostatin-dopamine chimeric analogs
EP2928469A4 (en) POLYMORPHIC FORMS OF DESAZADESFERRITHIOCIN ANALOGS
TWM433525U (en) Structure of calorifier
IL233446A0 (en) Polymorphic forms of paramphenel